Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Pancreatic Neoplasms 358Carcinoma, Non-Small-Cell Lung 178Neoplasms 109Breast Neoplasms 97Lung Neoplasms 81Urinary Bladder Neoplasms 79Neoplasm Metastasis 74Ovarian Neoplasms 53Cholangiocarcinoma 39Sarcoma 38Lymphoma 38Biliary Tract Neoplasms 35Gallbladder Neoplasms 34Hodgkin Disease 30Lymphoma, Non-Hodgkin 27Adenocarcinoma 27Lymphoma, Large B-Cell, Diffuse 25Colorectal Neoplasms 24Bile Duct Neoplasms 23Triple Negative Breast Neoplasms 22Recurrence 22Fallopian Tube Neoplasms 22Unspecified Adult Solid Tumor, Protocol Specific 21Carcinoma, Transitional Cell 21Carcinoma, Ovarian Epithelial 21Urethral Neoplasms 20Carcinoma 17Adenocarcinoma of Lung 15Head and Neck Neoplasms 14Carcinoma, Renal Cell 14

Interventions

Dexamethasone 6Bortezomib 3pomalidomide 2ixazomib 2filanesib 2dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Steroids 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Calcium Dobesilate 2milatuzumab 1Thalidomide 1Sodium Selenite 1Radiotherapy 1Radiation 1Proteasome Inhibitors 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Melphalan 1Lenalidomide 1Gemcitabine 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Plasmacytoma × Gemcitabine × Clear all
NCT02506959 2025-03-18

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

M.D. Anderson Cancer Center

Phase 2 Completed
83 enrolled 11 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡